Brokerages Anticipate TG Therapeutics Inc (NASDAQ:TGTX) Will Post Quarterly Sales of $40,000.00

Equities research analysts predict that TG Therapeutics Inc (NASDAQ:TGTX) will post sales of $40,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 during the same quarter last year. The firm is expected to report its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that TG Therapeutics will report full year sales of $180,000.00 for the current fiscal year, with estimates ranging from $150,000.00 to $200,000.00. For the next year, analysts forecast that the firm will post sales of $15.31 million, with estimates ranging from $150,000.00 to $52.99 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 99,471.43% and a negative return on equity of 309.17%.

TGTX has been the topic of several recent research reports. Cantor Fitzgerald initiated coverage on shares of TG Therapeutics in a research report on Friday, March 29th. They set an “overweight” rating and a $17.00 price objective on the stock. B. Riley reiterated a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, June 11th. BidaskClub cut TG Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 16th. ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of TG Therapeutics in a research report on Friday, April 12th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.07.

TGTX traded down $0.07 during midday trading on Wednesday, hitting $8.16. 80,682 shares of the company’s stock traded hands, compared to its average volume of 1,945,632. The company’s fifty day moving average price is $7.46. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.72 and a current ratio of 1.72. TG Therapeutics has a one year low of $3.32 and a one year high of $13.98.

In other news, CEO Michael S. Weiss purchased 50,000 shares of TG Therapeutics stock in a transaction on Wednesday, June 26th. The stock was purchased at an average price of $7.04 per share, with a total value of $352,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sean A. Power sold 17,654 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $8.47, for a total value of $149,529.38. The disclosure for this sale can be found here. Corporate insiders own 14.20% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LPL Financial LLC acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $49,000. NumerixS Investment Technologies Inc acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $50,000. BNP Paribas Arbitrage SA boosted its holdings in shares of TG Therapeutics by 239.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 13,117 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 9,255 shares during the last quarter. National Asset Management Inc. acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $58,000. Finally, Stifel Financial Corp acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $59,000. 54.60% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Article: Why is the Consumer Price Index (CPI) important?

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.